InsiderTrades

Form 4 for OCUL OCULAR THERAPEUTIX, INC

Accepted 2023-02-01 00:00:00 ET · period of report 2023-01-30 · accession 0001104659-23-009410 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-02-01 2023-01-30 OCUL Mattessich Antony C. Pres, CEO, Dir A - Grant $0.00 +176.3K 465.9K +61% $0
D 2023-02-01 2023-01-30 OCUL Mattessich Antony C. Pres, CEO, Dir A - Grant $0.00 +536.9K 536.9K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-01-30 A A 176,300 $0.00 465,950 D — — (F1) On January 30, 2023, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. (F2) Includes 363,050 shares of common stock of the Company underlying unvested RSUs.
2 Derivative Stock Option (Right to Buy) 2023-01-30 A A 536,900 $0.00 536,900 D $3.88 · — to 2033-01-29 536,900 Common Stock (F3) Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.